Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

3755 - Association between PD-L1 expression and survival in early-stage non-small cell carcinoma

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Elisa Gálvez

Citation

Annals of Oncology (2018) 29 (suppl_8): viii483-viii487. 10.1093/annonc/mdy290

Authors

E. Gálvez1, C. Gálvez Muñoz2, A. Cotes Sanchís1, A. Gonzaga López1, M..M. Llorente Ostiategui1, M. Montero Gómez1, I. Aranda López3, C. Llorca Ferrandiz1

Author affiliations

  • 1 Oncología, Hospital General de Elda, 3600 - Elda/ES
  • 2 Cirugía Torácica, Hospital General de Alicante, Alicante/ES
  • 3 Anatomía Patológica, Hospital General de Alicante, Alicante/ES
More

Resources

Abstract 3755

Background

Programmed death-ligand 1 (PD-L1) is used to predict response to immunotherapy. Temporal variability in the expression of PD-L1 in tumor cells has been reported; we wanted to assess the prevalence and prognostic role of PD-L1 expression in patients with resected non-small cell lung carcinoma (NSCLC) in initial stages with negative ganglia.

Methods

We analyzed tumor tissue of 170 patients with NSCLC stages I and II (pN0), no adjuvant or neoadjuvant therapy. Immunohistochemical staining of PD-L1 (Dako PD-L1 IHC 22C3 pharmDx) was performed on sections of tissue microarrays (TMAs), being able to be carried out in 165 cases (97%). The results were correlated (Ji Square and Fisher test) with clinicopathological variables (gender, age, smoking, pathological stage, histological type, nuclear grade, Ki67). For the analysis of survival (disease-free (DFS) and overall (OS) survival), the curves of Kaplan-Meier were used with the test of the logarithmic ranges (log rank test), and the proportional method of Cox taking the negative values as reference.

Results

The median age was 66 years (IQR 60-73), 135 men and 35 women. Eighty-eight per cent of them were smokers. The median follow-up was 64 months (range 1-163). The distribution by stages was: 51% of pathological stage IA, 31% of IB stage and 18% corresponded to stage II with pN0. Regarding histology there were 57% adenocarcinomas, 34% squamous cell carcinomas and 7% large cell carcinomas. PD-L1 expression was detected in 28.8% of the cases: 19.8% of the adenocarcinoma tumours and 41.3% of the squamous subtypes. We found a PD-L1 expression greater than 5% in 24.7% of cases and 11.8% of the total showed a PD-L1 expression ≥ 50%. The median DFS was 59.6 months (IQR 27-85) and OS 64.2 months (IQR 39.9-94.9). A statistically significant association was observed between expression of PD-L1 and younger age (inverse relationship, p = 0,033) and histologic subtype (lower expression in squamous type, p = 0,029). Kaplan-Meier analysis showed less DFS in positive PD-L1 patients. No significant differences were observed in relation to overall survival.

Conclusions

The expression of PD-L1 is associated with morphological data of greater aggressiveness and is a risk factor for relapse in NSCLC in early stages without positive ganglia.

Clinical trial identification

Legal entity responsible for the study

Hospital General de Alicante.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.